Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease

Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function

(2015) Wendy E. Boertien et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease

(2015) Harpreet Bhutani et al.   KIDNEY INTERNATIONAL

Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

(2015) Arlene B. Chapman et al.   KIDNEY INTERNATIONAL

Autosomal dominant polycystic kidney disease: the changing face of clinical management

(2015) Albert C M Ong et al.   LANCET

Pharmacological management of polycystic kidney disease

(2014) Rudolf P Wüthrich et al.   EXPERT OPINION ON PHARMACOTHERAPY

Spanish guidelines for the management of autosomal dominant polycystic kidney disease

(2014) E. Ars et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Identification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study

(2014) Andrew P McGovern et al.   BMC Nephrology

Type of PKD1 Mutation Influences Renal Outcome in ADPKD

(2013) E. Cornec-Le Gall et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease

(2013) Wendy E. Boertien et al.   KIDNEY INTERNATIONAL

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function

(2013) Susan E. Shoaf et al.   KIDNEY INTERNATIONAL

Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany

(2013) Hartmut P.H. Neumann et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Tolvaptan in Autosomal Dominant Polycystic Kidney Disease

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Commentary on: Tolvaptan in Patients With Autosomal-Dominant Polycystic Kidney Disease

(2013) Peter Black et al.   UROLOGY

Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects

(2012) Susan E. Shoaf et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

(2012) Vicente E. Torres et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rationale and Design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3-4 Study

(2011) Vicente E. Torres et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years' Experience

(2011) E. Higashihara et al.   Clinical Journal of the American Society of Nephrology

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease

(2011) Maria V. Irazabal et al.   KIDNEY INTERNATIONAL

Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug

(2011) E. Meijer et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Vasopressin Directly Regulates Cyst Growth in Polycystic Kidney Disease

(2007) X. Wang et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY